Back

Comparative analysis of monthly weight-regain dynamics after discontinuation of semaglutide vs tirzepatide

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy for cardiovascular risk Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Giovanni Fazio

Polimedic, Palermo (Italy)

7 More presentations in this session

Presentation thumbnail
Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study
Doctor C. Gurevitz (Petah Tikva, IL)
Abstract Slides
Presentation thumbnail
Semaglutide demonstrates favorable safety profile with 43% reduction in serious adverse events in adults with established ASCVD: a systematic review and meta-analysis of randomized controlled trials
Doctor V. Purewal (Scottsdale, US)
Abstract Slides
Presentation thumbnail
Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics
Doctor K. Katogiannis (Athens, GR)
Abstract Slides
Presentation thumbnail
Tirzepatide confers superior cardiorenal protection compared to semaglutide in type 2 diabetes: insights from a large-scale propensity-matched real-world cohort
Doctor I. Zahan (Harefield, GB)
Abstract Slides
Presentation thumbnail
Prognostic outcomes of SGLT2 inhibitors versus metformin in patients with type 2 diabetes and acute myocardial infarction
Doctor H. Zhang (Tianjin, CN)
Abstract Slides

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy for cardiovascular risk

The Event

Event poster

ESC Congress 2026

29 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Weight loss is the easy part, the struggle is maintenance
28 August 2026
thumbnail
Congress Presentation
Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
28 August 2020
thumbnail
Congress Presentation
Blood pressure effect of semaglutide in patients with hypertension: an individual patient data analysis of randomised controlled trials
25 April 2024
thumbnail
Congress Presentation
Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources